Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
#950 most reported symptom for this vaccine
Anticoagulant therapy has been reported 21 times in association with Zoster Live (Zostavax) vaccination in VAERS. This represents 0.0% of all 140,312 reports for this vaccine.
Among these reports, 2 mentioned death (9.52%) and 14 involved hospitalization (66.7%).
Anticoagulant therapy is the #950 most frequently reported symptom for Zoster Live (Zostavax) out of 2827 total symptoms.
Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.
Seeing 21 reports of Anticoagulant therapy after Zoster Live (Zostavax) vaccination may seem alarming, but context is critical. With 140,312 total reports for this vaccine (representing many millions of doses), Anticoagulant therapy appears in only 0.0% of reports.
The 9.52% mortality rate among these reports is elevated, but this reflects the severity of the condition itself rather than vaccine causation.
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.